Pfizer Q1 Results FY26: Q1 PAT Soars 27.23% to ₹191.75 Crore; Revenue Up 7.14% YoY

Pfizer  Q1 Results FY26: Pfizer posted its Q1 results on 13th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹191.75 crores against revenue of ₹603.05 crores. During Q1 FY26, the profit increase of the company was recorded at 27.23% YoY, and the revenue increase for the same period was 7.14%. 

Pfizer Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Pfizer Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Pfizer clocked Q1 FY26 standalone revenue of ₹603.05 crores vs ₹562.86 crores. 
• On the profit front, Pfizer earned a consolidated PAT of ₹191.75 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹150.71 crore.
• As per the standalone figures, the quarterly PAT of Pfizer has increased by 27.23%, and revenue has increased by 7.14% YoY.

Pfizer Share Price Performance

On the opening bell of 14th August 2025, the shares of Pfizer opened at ₹24.75 per share. However, the initial gains are sustained as of now, and Pfizer shares are trading at ₹25.16 per share, lower than their opening price.  Considering the long-term performance, Pfizer shares have yielded close to -12.88% returns in the past 1 year, and 5-year returns stand at -30.23%. Over the maximum timeframe, the Pfizer share provided 1,231.22% returns to investors. 

What Analysts Expect Post Q1 Results?

As Pfizer has posted robust Q1 results for FY26, analysts are expecting positive trends in its share price. As per the analysts, Pfizer’s share price could reach ₹6,900.00 per share in the coming year, and in downtrends, the share price could hit the level of ₹5,220.00 per share. However, one must ignore the risk of volatility in the stock market and invest in Pfizer shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Medanta Q1 Results FY26: Q1 PAT Rises 49.60% to ₹159.01 Crore; Revenue Up 19.71% YoY

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Regaal Resources IPO GMP: Day 2 IPO Live Updates